Press Releases

 
Press Releases
  Date Title and Summary View
Dec 7, 2013
Los Angeles, CA – December 7, 2013 – Kite Pharma, Inc. (Kite), today announced that Dr. Arie Belldegrun, Executive Chairman and Founder of Kite Pharma, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 1:30 p.m. Pacific Time.  The conference will be held at the We...
Dec 7, 2013
LOS ANGELES, CA (December 7, 2013) -- Kite Pharma, Inc. (Kite), a clinical-stage biotechnology company focused on engineered autologous T cell therapy (eACT) products for cancer, today announced positive clinical data demonstrating that Kite’s most advanced product candidate can produce robust and ...
Aug 8, 2013
Los Angeles, CA - August 8, 2013 - Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of three leading experts in the areas of immunotherapy, chimeric antigen receptor (CAR) te...
May 30, 2013
Los Angeles, CA (May 30, 2013) -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing engineered autologous T cell therapy (eACT) products for cancer, today announced the appointment of Keith Nolop, M.D. as Chief Medical Officer. Dr. Nolop, who brings to Kite over 20 years of successful drug development experien...
May 15, 2013
Los Angeles, CA (May 15, 2013) -- Kite Pharma Inc. (Kite), a clinical stage biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has closed a $20 million private placement of shares of its Series A Preferred Stock. In addition to the $20 million in new funds, Kite converted $15 milli...
Oct 16, 2012
Los Angeles, CA, October 16, 2012--- Kite Pharma Inc. (Kite), a biotechnology company focused on developing innovative targeted immunotherapies for cancer, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer In...
Jul 11, 2011
LOS ANGELES - July 11, 2011 - Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Adrian Bot, M.D., Ph.D., as Chief Scientific Officer. Dr. Bot brings over 13 years of experience in the biopharmaceutical industry and expertise in discovery, research...
Mar 9, 2011
Los Angeles, CA, March 9, 2011 – Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, today announced that it has raised $15 million in an initial round of financing through a private placement with a syndicate of venture and qualified investors. Riverbank Capital Inc., a FINRA...
Sep 20, 2010
LOS ANGELES, Calif., September 20, 2010 – Kite Pharma, Inc., a biopharmaceutical company focused on developing innovative active immunotherapies for cancer, announced today the appointment of Gloria Lee, M.D., Ph.D., as Chief Medical Officer. Dr. Lee, who brings over 18 years of oncology clinical development...
Sep 16, 2010
LOS ANGELES, Calif., September 16, 2010 – Kite Pharma, Inc., a biopharmaceutical company, focused on developing innovative active immunotherapies for cancer, announced today the appointment of Aya Jakobovits, Ph.D. as President and Chief Executive Officer.  Dr. Jakobovits brings over 20 years of broad experience in the biotech in...
Page: FirstPrevious ...
19
= add release to Briefcase